Literature DB >> 23608423

Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study.

Francesco Cantiello1, Antonio Cicione, Andrea Salonia, Riccardo Autorino, Luigi Tucci, Immacolata Madeo, Rocco Damiano.   

Abstract

OBJECTIVE: To investigate the role periurethral fibrosis secondary to chronic prostatic inflammation as a potential contributing factor to the etiology of lower urinary tract symptoms (LUTS) in male patients.
METHODS: Periurethral prostate tissue from 30 consecutive patients who underwent retropubic radical prostatectomy for prostate cancer was analyzed. We circumferentially performed 16 periurethral core bench biopsies on each radical prostatectomy specimen to evaluate the extent of periurethral inflammatory infiltrate and collagen and elastin amount. The clinical and urodynamic findings and the collagen and elastin periurethral amount in patients with or without inflammation were compared using the Mann-Whitney U test and the Pearson χ(2) test. Spearman correlation analysis tested the association between variables.
RESULTS: Of the 30 patients, 21 (70%) presented with inflammatory infiltration and 9 (30%) had no inflammation. A significant difference was found between the 2 groups in International Prostate Symptom Score (IPSS; P = .03) and in urodynamics findings by Schafer class (P = .01) and Abrams Griffiths number (P = .002). The histologic evaluation showed a higher collagen quantity (P = .04) and lower, albeit not statistically significant, elastin amount (P = .19) in the inflammation group. A positive association was observed between IPSS with inflammation grading (r = 0.507; P = .004) and collagen content (r = 0.649; P <.001), whereas IPSS was correlated negatively with elastin content (r = -0.565; P = .001).
CONCLUSION: Prostate inflammation may induce fibrotic changes in periurethral prostatic tissues, and this may eventually promote urethral stiffness and LUTS. Patients experiencing prostate-related LUTS could benefit from anti-inflammatory therapies, used alone or combined with the currently prescribed regimen.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23608423     DOI: 10.1016/j.urology.2013.01.053

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  28 in total

1.  Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling.

Authors:  Ashlee Bell-Cohn; Daniel J Mazur; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-09

2.  Histotripsy of the Prostate in a Canine Model: Characterization of Post-Therapy Inflammation and Fibrosis.

Authors:  Sarah E Darnell; Timothy L Hall; Scott A Tomlins; Xu Cheng; Kimberly A Ives; William W Roberts
Journal:  J Endourol       Date:  2015-02-18       Impact factor: 2.942

3.  Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Authors:  Opal Lin-Tsai; Peter E Clark; Nicole L Miller; Jay H Fowke; Omar Hameed; Simon W Hayward; Douglas W Strand
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

4.  Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.

Authors:  Jill A Macoska; Kristen S Uchtmann; Glen E Leverson; Kevin T McVary; William A Ricke
Journal:  J Urol       Date:  2019-06-12       Impact factor: 7.450

Review 5.  Causal contributors to tissue stiffness and clinical relevance in urology.

Authors:  Laura Martinez-Vidal; Valentina Murdica; Chiara Venegoni; Filippo Pederzoli; Marco Bandini; Andrea Necchi; Andrea Salonia; Massimo Alfano
Journal:  Commun Biol       Date:  2021-08-26

Review 6.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

7.  Intraurethral injection with LPS: an effective experimental model of prostatic inflammation.

Authors:  Fabiana Oliveira Dos Santos Gomes; Amanda Costa Oliveira; Edlene Lima Ribeiro; Bruna Santos da Silva; Laise Aline Martins Dos Santos; Ingrid Tavares de Lima; Amanda Karolina Soares E Silva; Shyrlene Meiry da Rocha Araújo; Terezinha Gonçalves; Mario Ribeiro de Melo-Junior; Christina Alves Peixoto
Journal:  Inflamm Res       Date:  2017-11-18       Impact factor: 4.575

8.  Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis.

Authors:  Letitia Wong; Paul R Hutson; Wade Bushman
Journal:  Prostate       Date:  2014-10-04       Impact factor: 4.104

9.  Prostatic collagen architecture in neutered and intact canines.

Authors:  Hannah Ruetten; Kyle A Wegner; Michael F Romero; Michael W Wood; Paul C Marker; Douglas Strand; Sara A Colopy; Chad M Vezina
Journal:  Prostate       Date:  2018-05-08       Impact factor: 4.104

10.  Smoothened inhibition leads to decreased cell proliferation and suppressed tissue fibrosis in the development of benign prostatic hyperplasia.

Authors:  Jianmin Liu; Jing Yin; Ping Chen; Daoquan Liu; Weixiang He; Yan Li; Mingzhou Li; Xun Fu; Guang Zeng; Yuming Guo; Xinghuan Wang; Michael E DiSanto; Xinhua Zhang
Journal:  Cell Death Discov       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.